Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 33 sources its claims cite were checked for support.

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia

Open access

Abstract

BACKGROUND: -acetylgalactosamine-conjugated antisense oligonucleotide that targets the messenger RNA of apolipoprotein C-III, which inhibits triglyceride clearance. METHODS: In this phase 3, international, double-blind, randomized, placebo-controlled trial, we enrolled patients with moderate hypertriglyceridemia (triglyceride level, 150 to 499 mg per deciliter) and elevated cardiovascular risk or with severe hypertriglyceridemia (triglyceride level, ≥500 mg per deciliter) and randomly assigned them in a 1:3 ratio to a 50-mg or 80-mg cohort. The patients were then randomly assigned in a 3:1 ratio to receive monthly subcutaneous olezarsen or matching placebo within each cohort. The primary outcome was the least-squares mean percent change in triglyceride level from baseline to 6 months among the patients with moderate hypertriglyceridemia, reported as the difference between each olezarsen dose group and the placebo group (the placebo-adjusted change). RESULTS: A total of 1349 patients (254 in the olezarsen 50-mg group, 766 in the olezarsen 80-mg group, and 329 in the placebo group) were included in the primary efficacy analysis. The median age was 64 years, 40% of the patients were women, and the median triglyceride level at baseline was 238.5 mg per deciliter (interquartile range, 190.5 to 307.5). At 6 months, the placebo-adjusted least-squares mean change in triglyceride level was -58.4 percentage points (95% confidence interval [CI], -65.1 to -51.7; P<0.001) in the olezarsen 50-mg group and -60.6 percentage points (95% CI, -67.1 to -54.0; P<0.001) in the olezarsen 80-mg group. The incidence of serious adverse events appeared to be similar across the trial groups. CONCLUSIONS: Among patients with moderate hypertriglyceridemia and elevated cardiovascular risk, treatment with olezarsen resulted in significantly greater reduction in triglyceride levels at 6 months than placebo. (Funded by Ionis Pharmaceuticals; ESSENCE-TIMI 73b ClinicalTrials.gov number, NCT05610280.).

Overview

CoChat Summary

TL;DR

In the phase 3 ESSENCE-TIMI 73b trial, monthly olezarsen reduced triglyceride levels at 6 months in patients with moderate hypertriglyceridemia and elevated cardiovascular risk. Placebo-adjusted least-squares mean changes were −58.4 percentage points with 50 mg and −60.6 percentage points with 80 mg, with serious adverse events appearing similar across groups.

Key findings

  • In the primary efficacy population (N=1349), the placebo-adjusted least-squares mean change in triglyceride level from baseline to 6 months was −58.4 percentage points (95% CI, −65.1 to −51.7; P<0.001) in the olezarsen 50-mg group and −60.6 percentage points (95% CI, −67.1 to −54.0; P<0.001) in the 80-mg group.
  • At 12 months, the placebo-adjusted least-squares mean change in triglyceride level was −50.7 percentage points in both olezarsen groups (95% CI, −60.6 to −40.7 and −60.3 to −41.1; P<0.001 for both). At 6 months, 85.0% of the 50-mg group, 88.7% of the 80-mg group, and 12.5% of the placebo group had a triglyceride level below 150 mg/dL; at 12 months, the corresponding percentages were 82.8%, 85.0%, and 20.6%.
  • At 6 months, placebo-adjusted changes were −61.7 and −69.8 percentage points for apolipoprotein C-III, −66.1 and −68.4 for remnant cholesterol, −21.9 and −21.7 for non-HDL cholesterol, −56.6 and −57.4 for VLDL cholesterol, +45.5 and +47.6 for HDL cholesterol, and −14.7 and −14.9 for apolipoprotein B in the 50-mg and 80-mg groups, respectively. LDL cholesterol showed no apparent change versus placebo (−1.1 and −1.5 percentage points; P=0.72 and P=0.51).
  • Serious adverse events occurred in 9.4% of the 50-mg group, 13.6% of the 80-mg group, and 11.4% of the placebo group. Injection-site reactions were more common with olezarsen (15.2% and 16.2%) than placebo (1.6%). Major adverse cardiovascular events occurred in 2.8%, 5.7%, and 4.3%, respectively; acute pancreatitis occurred in 0, 3 (0.4%), and 0 patients.

Methods

  • Phase 3, international, double-blind, randomized, placebo-controlled trial conducted at 160 sites in North America and Europe from November 2022 through February 2024. Patients had moderate hypertriglyceridemia (triglyceride level 150 to 499 mg/dL) plus elevated cardiovascular risk or severe hypertriglyceridemia (≥500 mg/dL).
  • Patients were randomly assigned 1:3 to a 50-mg or 80-mg cohort, then 3:1 within each cohort to monthly subcutaneous olezarsen or matching placebo; treatment lasted 12 months with a 13-week safety follow-up.
  • The primary efficacy population included patients with baseline triglyceride level <500 mg/dL who received at least one dose (254 in the 50-mg group, 766 in the 80-mg group, 329 in the placebo group). The primary outcome was the placebo-adjusted least-squares mean percent change in triglyceride level from baseline to 6 months, analyzed with ANCOVA including baseline triglyceride level and a retrieved dropout-based multiple-imputation approach.

Limitations

  • The paper states the trial was primarily designed to assess olezarsen in moderate hypertriglyceridemia rather than across the full range of triglyceride levels; two phase 3 trials are specifically evaluating severe hypertriglyceridemia.
  • The paper states efficacy and safety beyond 1 year were not assessed, and the majority of patients were White, so results may not be generalizable to other races and ethnic groups.
  • Evident from the text: the trial was not powered for clinical outcomes such as major adverse cardiovascular events or acute pancreatitis, which were adjudicated but not primary endpoints; the observed fibrate interaction was noted by the authors as possibly attributable to chance.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2507227

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

9 Valid · 2 Not valid · 5 Not checked · 65 Own results and interpretations

47 more claims

Create a free account to see all 81 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 13

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 78

Metadata

Authors
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., Zhang, S., Li, D., Banach, M., Stroes, E., Lu, M. T., Tsimikas, S., Giugliano, R. P., & Sabatine, M. S.
Affiliations
  • Brigham and Women's Hospital (US)
  • Ionis Pharmaceuticals (United States) (US)
  • TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston
  • Medical University of Lodz (PL)
  • Amsterdam University Medical Centers (NL)
  • Harvard University (US)
Venue
New England Journal of Medicine
Published
2025-10-02
Volume
393
Issue
13
Pages
1279-1291
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4413853946
Cited by
78
References
32
Citations by year
2026: 66 · 2025: 12
FWCI
54.03
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
Funders
Ionis Pharmaceuticals
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
olezarsen, apolipoprotein C-III, antisense oligonucleotides, hypertriglyceridemia, triglyceride lowering, triglyceride clearance, cardiovascular risk, severe hypertriglyceridemia, dose comparison, serious adverse events, lipid-lowering therapy, triglyceride-rich lipoproteins, hepatic VLDL secretion
MeSH terms
Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Oligonucleotides, Severity of Illness Index, Triglycerides, Hypertriglyceridemia, Oligonucleotides, Antisense, Treatment Outcome, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. https://app.cochat.ai/papers/10.1056/nejmoa2507227
The paper
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., Zhang, S., Li, D., Banach, M., Stroes, E., Lu, M. T., Tsimikas, S., Giugliano, R. P., & Sabatine, M. S. (2025). Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2507227

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.